NOGA Therapeutics
Gene Therapies for Severe and Chronic Illnesses
Company Overview
Snapshot
Founded in January 2020 by Noam Baumatz, NOGA Therapeutics operates with 1–10 employees. The company has raised $1M across two funding rounds from two investors. In April 2024, NOGA Therapeutics secured funding from PipelBiz.
Business overview
NOGA Therapeutics is a gene therapy company focused on developing transformative treatments for severe and chronic illnesses by reprogramming blood stem cells. Utilizing advanced lentiviral vector technology, the company aims to induce targeted production of essential proteins within specific cells and tissues. Its therapeutic pipeline includes DopaGene for Parkinson’s disease, along with treatments for X-linked Agammaglobulinemia (XLA), lysosomal storage diseases, and inflammatory bowel disease (IBD). NOGA Therapeutics operates within the Health Tech & Life Sciences sector, specifically targeting the Pharma & Medical Biotechnology and Drugs Discovery & Development industries with its cell-based biological solutions.
Log in to access full profile ›Company Intelligence Q&A
- When was NOGA Therapeutics founded and by whom?
- NOGA Therapeutics was founded in January 2020 by Noam Baumatz.
- What is NOGA Therapeutics' primary focus?
- NOGA Therapeutics focuses on gene therapies for severe and chronic illnesses, utilizing blood stem cell reprogramming and advanced lentiviral vector technology to produce essential proteins in targeted cells and tissues.
- What is the status of NOGA Therapeutics' product pipeline?
- NOGA Therapeutics' product pipeline is currently in the clinical trial stage, with products like DopaGene for Parkinson's disease and treatments for X-linked Agammaglobulinemia (XLA), lysosomal storage diseases, and inflammatory bowel disease (IBD).
- Which investors have participated in NOGA Therapeutics' funding rounds?
- NOGA Therapeutics has received funding from investors including Lonza and PipelBiz.